-
Mashup Score: 3Oncology information and materials | Astellas Pharma Ltd - 14 day(s) ago
Astellas has made an enduring commitment to the field of Oncology, channelling our expertise in developing treatments to help meet the challenges faced by patients and their
Source: www.astellas.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Partnering - 25 day(s) ago
Astellas’ competitiveness comes from an extensive global research network featuring cutting-edge technology and active collaboration with academia and bio-venture companies worldwide.
Source: www.astellas.comCategories: General Medicine NewsTweet-
We pioneer science in breakthrough areas of R&D and know partnering is essential to achieve more for patients, sooner. If you are a like-minded, ambitious innovator, come and meet us at #BIO2025, June 16-19, Boston, or get in touch here: https://t.co/yRpAonGGQF https://t.co/EnTpeBCsSC
-
-
Mashup Score: 3Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 - 1 month(s) ago
– Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 — XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study of patients with solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer –
Source: www.astellas.comCategories: General Medicine NewsTweet-
We’re pleased to share that Astellas has entered into an exclusive license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage #ADC targeting CLDN18.2. Learn more: https://t.co/3NLiRhVvs6 https://t.co/koEN9k1RFX
-
-
Mashup Score: 330Oncology information and materials | Astellas Pharma Ltd - 2 month(s) ago
Astellas has made an enduring commitment to the field of Oncology, channelling our expertise in developing treatments to help meet the challenges faced by patients and their
Source: www.astellas.comCategories: General Medicine NewsTweet-
For UK healthcare professionals only. If you’re not a healthcare professional, you can learn more here: https://t.co/v3ulME6PAK UK healthcare professionals can access my focused video on the topic below using this link https://t.co/cGjYHnJbW6 Sponsored by Astellas Pharma Ltd https://t.co/CY7Ioge2Vb
-
-
Mashup Score: 4Primary Focus Blindness & Regeneration - 5 month(s) ago
Astellas’ mission is to free patients from the fear of vision loss, and offer the hope of recovery of lost sight.
Source: www.astellas.comCategories: General Medicine News, PayerTweet-
Low vision simulation goggles have given us a glimpse into the experience of people living with retinal diseases like age-related macular degeneration (AMD). Learn about our commitment to the low vision community: https://t.co/sIpkESKNPo #AMDAwarenessMonth For U.S. Audiences Only https://t.co/Z7qH2vp16P
-
-
Mashup Score: 10Oncology information and materials | Astellas Pharma Ltd - 5 month(s) ago
Astellas has made an enduring commitment to the field of Oncology, channelling our expertise in developing treatments to help meet the challenges faced by patients and their
Source: www.astellas.comCategories: General Medicine News, Hem/OncsTweet-
For UK healthcare professionals only. If you’re not a healthcare professional, you can learn more here: https://t.co/v3ulME6PAK UK healthcare professionals can access my focused video on the topic below using this link https://t.co/cGjYHnJbW6 Sponsored by Astellas Pharma Ltd https://t.co/CY7Ioge2Vb
-
-
Mashup Score: 3
– China has the highest number of cases and deaths from gastric cancer of any country worldwide1 — Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker expressed by 35% of Chinese patients with advanced gastric and gastroesophageal junction (GEJ) cancer2 –
Source: www.astellas.comCategories: General Medicine News, PayerTweet-
Our claudin 18.2-targeted therapy has been approved in China for the treatment of advanced gastric/GEJ cancer, offering a new precision medicine option for these patients' cancer care. Read: https://t.co/ptbebaUmeq #GastricCancer #CancerResearch For U.S. audiences only.
-
-
Mashup Score: 12Astellas Provides Update on IZERVAY™ (avacincaptad pegol intravitreal solution) Supplemental New Drug Application - 7 month(s) ago
TOKYO, Nov.19, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on November 15, 2024, regarding the supplemental New Drug Application (sNDA) for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The sNDA sought to include positive two-year data in the U.S.
Source: www.astellas.comCategories: General Medicine News, General HCPsTweet-
RT @adamfeuerstein: Astellas Izervay 2yr data rejected by FDA. https://t.co/RmRhbaAUyB $APLS
-
-
Mashup Score: 2Primary Focus Blindness & Regeneration - 8 month(s) ago
Astellas’ mission is to free patients from the fear of vision loss, and offer the hope of recovery of lost sight.
Source: www.astellas.comCategories: General Medicine News, PayerTweet-
As @aao_ophth 2024 wraps up in Chicago, we're energized by our discussions about geographic atrophy (GA), the insights from the AI symposium and the engaging activities at our booth. Learn more about our commitment: https://t.co/ul7b0PCe0w #AAO2024 For U.S. audiences only. https://t.co/FTOUH6kFzt
-
-
Mashup Score: 0
TOKYO, September 18, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that DIGITIVA™, a non-invasive digital health solution for heart failure management, has been listed with the U.S. Food and Drug Administration (FDA). DIGITIVA is classified as a Class I Software as a Medical Device (SaMD) and is exempt from 510(k) premarket submission*. DIGITIVA is the first digital health offering from Astellas in the U.S.
Source: www.astellas.comCategories: General Medicine News, Future of MedicineTweet-
.@AstellasUS Announces #FDA Listing of#SaMD DIGITIVA™ for at-home disease mgmt of #HeartFailure. 3 components: #DigitalStethoscope by @Eko_Health smartphone app built on @Welldoc educational content from @American_Heart + dedicated clinical review team https://t.co/qA9l8eClGY
-
For UK healthcare professionals only. If you’re not a healthcare professional, you can learn more here: https://t.co/v3ulME6PAK UK healthcare professionals can access my focused video on the topic below using this link https://t.co/cGjYHnJbW6 Sponsored by Astellas Pharma Ltd https://t.co/CY7Ioge2Vb